Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis

Overview

Journal Chin J Integr Med

Date 2023 May 23

PMID 37221412

Authors

Xing-Xing Li

Dong Li

Xiao-Yun Cui

Kun Zhou

Jing Liu

Jin-Jin Lu

Yang Wu

Qian Lin

Yan Li

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the cardioprotective effects of astragaloside IV (AS-IV) in heart failure (HF).

Methods: PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, Chinese Bio-medical Literature and Retrieval System (SinoMed), China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched from inception to November 1, 2021 for animal experiments to explore AS-IV in treating HF in rats or mice. The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular weight-to-body weight (LVW/BW) and B-type brain natriuretic peptide (BNP) were recorded. The qualities of included studies were assessed by the risk of bias according to the Cochrane handbook. Meta-analysis was performed using Stata 13.0.

Results: Twenty-one articles involving 558 animals were considered. Compared with the control group, AS-IV improved cardiac function, specifically by increasing LVEF (mean difference (MD)=6.97, 95% confidence interval (CI)=5.92 to 8.03, P<0.05; fixed effects model) and LVFS (MD=7.01, 95% CI=5.84 to 8.81, P<0.05; fixed effects model), and decreasing LVEDD (MD=-4.24, 95% CI=-4.74 to -3.76, P<0.05; random effects model) and LVESD (MD=-4.18, 95% CI=-5.26 to -3.10, P<0.05; fixed effects model). In addition, the BNP and LVW/BW levels were decreased in the AS-IV treatment group (MD=-9.18, 95% CI=-14.13 to -4.22, P<0.05; random effects model; MD=-1.91, 95% CI=-2.42 to -1.39, P<0.05; random effects model).

Conclusions: AS-IV is a promising therapeutic agent for HF. However, this conclusion needs to be clinically validated in the future.

Citing Articles

Efficacy and safety of formula in the treatment of coronary microvascular disease: A randomized, double-blind, placebo-controlled clinical trial study.

Xie F, Wang Y, Zhang L, Zhu W, Cheng J, Lu Y Heliyon. 2024; 10(16):e35747.

PMID: 39253205 PMC: 11381722. DOI: 10.1016/j.heliyon.2024.e35747.

Dahuang Zhechong Pill Improves Pulmonary Fibrosis through miR-29b-2-5p/HK2 Mediated Glycolysis Pathway.

He X, Liang J, Xiao J, Li X, Zhang X, Chen D Chin J Integr Med. 2024; .

PMID: 39231918 DOI: 10.1007/s11655-024-3765-x.

Modulation of the vitamin D receptor by traditional Chinese medicines and bioactive compounds: potential therapeutic applications in VDR-dependent diseases.

Yao M, Oduro P, Akintibu A, Yan H Front Pharmacol. 2024; 15:1298181.

PMID: 38318147 PMC: 10839104. DOI: 10.3389/fphar.2024.1298181.

References

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. View

Rossignol P, Hernandez A, Solomon S, Zannad F . Heart failure drug treatment. Lancet. 2019; 393(10175):1034-1044. DOI: 10.1016/S0140-6736(18)31808-7. View

Zang Y, Wan J, Zhang Z, Huang S, Liu X, Zhang W . An updated role of astragaloside IV in heart failure. Biomed Pharmacother. 2020; 126:110012. DOI: 10.1016/j.biopha.2020.110012. View

Dai H, Jia G, Lu M, Liang C, Wang Y, Wang H . Astragaloside IV inhibits isoprenaline‑induced cardiac fibrosis by targeting the reactive oxygen species/mitogen‑activated protein kinase signaling axis. Mol Med Rep. 2017; 15(4):1765-1770. DOI: 10.3892/mmr.2017.6220. View

Tang B, Zhang J, Tan H, Wei X . Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure. Biosci Rep. 2018; 38(3). PMC: 6048210. DOI: 10.1042/BSR20171036. View

Chen C, Lin Q, Zhu X, Xia J, Mao T, Chi T . Pre-clinical Evidence: Berberine as a Promising Cardioprotective Candidate for Myocardial Ischemia/Reperfusion Injury, a Systematic Review, and Meta-Analysis. Front Cardiovasc Med. 2021; 8:646306. PMC: 8187562. DOI: 10.3389/fcvm.2021.646306. View

10.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

11.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

12.

Borenstein M, Hedges L, Higgins J, Rothstein H . A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2015; 1(2):97-111. DOI: 10.1002/jrsm.12. View

13.

Ji Y, Wang T, Zhang X, Li L, Li L, Guo Y . Astragalosides increase the cardiac diastolic function and regulate the "Calcium sensing receptor-protein kinase C-protein phosphatase 1" pathway in rats with heart failure. Biomed Pharmacother. 2018; 103:838-843. DOI: 10.1016/j.biopha.2018.04.111. View

14.

Nie P, Meng F, Zhang J, Wei X, Shen C . Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway. Oxid Med Cell Longev. 2019; 2019:4625912. PMC: 6594267. DOI: 10.1155/2019/4625912. View

15.

Sui Y, Wang Y, Liu L, Liu F, Zhang Y . Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol. 2019; 57(1):48-54. PMC: 8871603. DOI: 10.1080/13880209.2019.1569697. View

17.

Sui Y, Zhang K, Ren Y, Liu L, Liu Y . The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure. Pharm Biol. 2020; 58(1):1192-1198. PMC: 7717863. DOI: 10.1080/13880209.2020.1849319. View

18.

Shi H, Zhou P, Gao G, Liu P, Wang S, Song R . Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem. 2021; 45(7):e13757. DOI: 10.1111/jfbc.13757. View

19.

Wang Q, Yang X, Song Y, Sun X, Li W, Zhang L . Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy. Life Sci. 2021; 275:119414. DOI: 10.1016/j.lfs.2021.119414. View

20.

Yin B, Hou X, Lu M . Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways. Acta Pharmacol Sin. 2018; 40(5):599-607. PMC: 6786296. DOI: 10.1038/s41401-018-0082-y. View

21.

Dong Z, Zhao P, Xu M, Zhang C, Guo W, Chen H . Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation. Sci Rep. 2017; 7(1):2691. PMC: 5457407. DOI: 10.1038/s41598-017-02360-5. View

22.

Liu Z, Liu H, Wang J . Astragaloside IV protects against the pathological cardiac hypertrophy in mice. Biomed Pharmacother. 2018; 97:1468-1478. DOI: 10.1016/j.biopha.2017.09.092. View

23.

Liu J, Li Y, Bian X, Xue N, Yu J, Dai S . Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1. Exp Ther Med. 2021; 22(4):1076. PMC: 8355636. DOI: 10.3892/etm.2021.10510. View

24.

Jia G, Leng B, Wang H, Dai H . Inhibition of cardiotrophin‑1 overexpression is involved in the anti‑fibrotic effect of Astrogaloside IV. Mol Med Rep. 2017; 16(6):8365-8370. DOI: 10.3892/mmr.2017.7676. View